All In Biotech

Drug Trial Radar · NCT01453153

Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer

A Phase 1b/2 Multicenter, International, Randomized, Double Blind, Placebo-Controlled, Study of Gemcitabine Combined With PEGPH20 Compared to Gemcitabine Combined With Placebo in Patients With Stage IV Previously Untreated Pancreatic Cancer

Last checked: Nov 19, 2026Latest source record: Nov 30, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

28

Actual

Start

Sep 2011

Primary completion

Feb 2014

Study completion May 2015

Sponsor

Lead sponsor
Halozyme TherapeuticsIndustry
Sponsor type
Industry
First posted
Oct 17, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1B: Open label (all patients receive PEGPH20+gemcitabine), dose escalation, safety and tolerability study to determine the safe dose of PEGPH20 to use in combination with gemcitabine in Stage IV previously untreated pancreatic cancer patients. Phase 2: Randomized, double blind study to compare the effect of overall survival of gemcitabine plus PEGPH20 vs gemcitabine plus placebo in Stage IV previously untreated pancreatic cancer patients.

Conditions

  • Stage IV Pancreatic Cancer

Interventions

  • GemcitabineDrug

    1000 mg/m2 given IV one time a week (Cycle 1: 7 weeks on treatment, 1 week off treatment; Cycle 2+: 3 Weeks on treatment, 1 week off treatment)

  • PEGPH20Drug

    (Cycle 1: 7 weeks on treatment/1 week off treatment; Cycle 2+: 3 Weeks on treatment/1 week off treatment). Doses start at 1.0 mcg/kg and modified until recommended Phase 2 dose is determined. Treatment continues until occurrence of significant treatment-related toxicity, progressive disease, or discontinuation criteria are met

  • PlaceboDrug

    (Cycle 1: 7 weeks on treatment/1 week off treatment; Cycle 2+: 3 Weeks on treatment/1 week off treatment).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With a Dose-limiting Toxicity (DLT)Time frame: first 4 weeks of Cycle 1
  2. Recommended Phase 2 Dose (RP2D)Time frame: first 4 weeks of Cycle 1

Locations

12 sites in 2 countries. Site status is shown where the registry gives one.

  • Highlands Oncology Group

    Fayetteville, Arkansas

  • California Pacific Medical Center

    San Francisco, California

  • Indiana University Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana

  • UMDNJ - New Jersey Medical School

    Newark, New Jersey

  • NSLIJ Health System, Monter Cancer Center

    New Hyde Park, New York

  • Mount Sinai School of Medicine

    New York, New York

  • SUNY Upstate Medical University

    Syracuse, New York

  • Seattle Cancer Care Alliance

    Seattle, Washington

  • Chelyabinsk Regional Clinical Oncology Center

    Chelyabinsk, Russia

  • Russian Oncological Research Center n.a. N.N. Blokhin

    Moscow, Russia

  • Medical Radiological Research Center

    Obninsk, Russia

  • Omsk Regional Budget Medical Institution

    Omsk, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.